ReviewCancers2026

The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer.

Hyejee Ohm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.